Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Norgine submits MAA to EMA for eflornithine in high-risk neuroblastoma
Norgine filed a marketing authorisation application to EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by FDA for HRNB, shows improved survival rates. Norgine aims to provide new treatment options, addressing the high unmet medical need in pediatric oncology.
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine in high-risk neuroblastoma
Norgine filed a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma (HRNB), following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA as the first oral maintenance therapy for HRNB, showed improved survival rates. Norgine aims to provide additional treatment options for HRNB patients.
Norgine Files Marketing Authorization for Eflornithine in High-Risk Neuroblastoma
Norgine filed a marketing authorisation application to EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. This aims to provide a new treatment option in paediatric oncology. Norgine, in partnership with USWM, LLC, plans to commercialise eflornithine in Europe, Australia, and New Zealand. FDA approved eflornithine as the first oral maintenance therapy for HRNB in December 2023, based on improved survival outcomes in trials.
Norgine submits Marketing Authorisation Application to the EMA for eflornithine in high-risk neuroblastoma
Norgine filed a marketing authorisation application to the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA for reducing relapse risk in HRNB, shows improved survival rates. Norgine aims to provide new treatment options for pediatric oncology patients.
Norgine submits Marketing Authorisation Application to the EMA for Eflornithine in High-Risk Neuroblastoma
Norgine filed a marketing authorisation application with the EMA for eflornithine in high-risk neuroblastoma, following submissions in Australia, Switzerland, and the UK. Eflornithine, approved by the FDA for HRNB, showed improved survival rates. Norgine aims to provide new treatment options for pediatric oncology patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath